Memantine for the treatment of frontotemporal dementia: a meta-analysis
Received 14 August 2015
Accepted for publication 20 October 2015
Published 12 November 2015 Volume 2015:11 Pages 2883—2885
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Professor Wai Kwong Tang
Taro Kishi, Shinji Matsunaga, Nakao Iwata
Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Japan
Background: There is no conclusive evidence supporting the efficacy of memantine in frontotemporal dementia (FTD). We conducted a comprehensive meta-analysis of memantine concerning the efficacy and tolerability of memantine in FTD.
Methods: Studies were identified through searches of PubMed, databases of the Cochrane Library, and PsycINFO citations up to April 10, 2015. Outcomes were Clinical Global Impression (primary), Mini-Mental State Examination, Neuropsychiatric Inventory, and Zarit Burden Interview scores as well as all-cause discontinuation. Standardized mean difference and risk ratio with 95% confidence interval were calculated.
Results: Two randomized controlled trials (RCTs) (total n=130) met the inclusion criteria. Memantine was marginally superior to placebo as assessed by the Clinical Global Impression scores (standardized mean difference =-0.34, 95% confidence interval =-0.68–0.01, P=0.06). However, there were no significant differences in Mini-Mental State Examination, Neuropsychiatric Inventory, and Zarit Burden Interview scores as well as all-cause discontinuation between memantine and placebo.
Conclusion: Our results suggest that memantine may benefit FTD patients. However, because only two randomized controlled trials have addressed this issue, further studies using larger samples are needed.
Keywords: frontotemporal dementia, memantine, meta-analysis, Clinical Global Impression
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]